Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
SOUTH SAN FRANCISCO, Calif., March 24, 2016 -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced that it will host a conference call today, Thursday, March 24, 2016, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), to provide a company update.
Conference Call Details
To access the live conference call, please dial (844) 452-6828 from the U.S. and Canada or +1 (765) 507-2588 internationally, and use the passcode 79012351. Please dial in 10 minutes prior to the start of the call.
To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the Company’s website at http://investors.portola.com. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. A replay of the webcast will be available on the Company’s website for 14 days following the live event.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three programs using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success. These programs include betrixaban, an oral, once-daily Factor Xa inhibitor; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart W2O Group [email protected]
